A comparison of ELT and SLT

Article

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma.

A study by Italian researchers, the results of which have been published online by Eye, has found that both excimer laser trabeculotomy (ELT) and selective laser trabeculoplasty (SLT) are both equally effective treatment options for primary open angle glaucoma (POAG) refractory to medical therapy.

Silvia Babighian and colleagues from St Antonio Hospital in Padova, Italy sought to compare the safety and efficacy of ELT and SLT as a treatment for patients with POAG over a 24 month follow-up period. The prospective, randomized study consisted of 30 consecutive eyes assigned randomly to receive either of the treatments. ELT was performed with the XeCl excimer laser with an emission wavelength of 308 nm, with eight laser spots equally distributed over the anterior trabeculum. The SLT procedures were carried out with a frequency doubled q-switched neodymium : yytrium-aluminum-garnet laser. Approximately 50 adjacent laser spots were distributed over 180° of the trabecular meshwork. Procedure success was defined as a ≥20% reduction in IOP.

After 24 months, success in the ELT group was 53.3% and 40% in the SLT group. Mean IOP decreased 25.0±1.9 to 17.6±2.2 mmHg and from 23.9±0.9 to 19.1±1.8 mmHg in the ELT and SLT groups, respectively.

Babighian and colleagues were able to conclude that both techniques are effective in treating POAG.

Click here for full abstract.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
© 2025 MJH Life Sciences

All rights reserved.